NCT05873595终止不适用
Clinical Understanding Through Real-world Data to Validate Effectiveness of Treatments in Peyronie's Disease
Endo Pharmaceuticals7 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2023年6月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 29
- 试验地点
- 7
- 主要终点
- Number of Participants Receiving Each Treatment Type for PD
研究概览
简要总结
This is an observational study, meaning participants will not receive any investigational treatment as part of this study.
Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.
详细描述
Each participant of the study will have their data collected from the date of confirmed diagnosis of PD to the date of enrollment in the registry, post consent. Data will be collected from the participant's clinical records as well as from the participant directly. Data will be collected through Pulse Infoframe's technology platform.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Any adult with a confirmed clinical diagnosis of PD.
- •Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment.
- •Willing to participate in the registry (including completion of ePROs) and complete the informed consent form.
- •Having received PD treatment within 2 weeks before enrollment, at enrollment or any time after the date of enrollment. After a confirmed diagnosis of PD, not having received PD treatment.
- •Able to participate in English based registry.
- •Key Exclusion criteria:
- •Not having a clinical diagnosis of PD.
- •Age less than 18 years.
- •Do not provide informed consent.
排除标准
- 未提供
结局指标
主要结局
Number of Participants Receiving Each Treatment Type for PD
时间窗: Up to 12 months
次要结局
- Participant Satisfaction Questionnaire(Up to 12 months)
- Number of Participants Receiving Post-Procedural Care by the Treating Physician(Up to 12 months)
- Change from Baseline in Peyronie's Disease Questionnaire (PDQ) Score(Up to 12 months)
- Change from Baseline in International Index of Erectile Function (IIEF) Score(Up to 12 months)
- Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score(Up to 12 months)
- Change from Baseline in Beck Anxiety Inventory (BAI) Scale Score(Up to 12 months)
研究者
研究点 (7)
Loading locations...
相似试验
终止
不适用
Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's ContractureDupuytren's ContractureNCT05877066Endo Pharmaceuticals130
尚未招募
不适用
Investigating the Experiences of Individuals With Gastric Cancer Participating in Clinical TrialsGastric CancerNCT05699278Power Life Sciences Inc.500
已完成
不适用
Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast CancerBreast CancerNCT02551263Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan201
招募中
4 期
Study the effectiveness of Hydroxyzine hydrochloride in Patients with Persistent ItchingCTRI/2017/06/008847Dr Reddys Laboratories Ltd400
已完成
不适用
An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR GenesPOMC Deficiency ObesityPCSK1 Deficiency ObesityLEPR Deficiency ObesityNCT03621007Rhythm Pharmaceuticals, Inc.8